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background: Obesity and overweight are significantly involved in several reproductive pathologies contributing to infertility in men and
women. In addition, several cancers of the reproductive system, such as endometrial, ovarian, breast, testicular and prostate cancers, are strongly
influenced by obesity. However, the molecular mechanisms involved in the association between obesity and reproductive disorders remain unclear.
Our proposal is to review the current scientific evidence regarding the effect of obesity-related factors as the core of the collective mechanisms dir-
ectly and indirectly involved in the relationship between obesity and reproductive disorders, with a special and original focus on the effect of the
obesity state microenvironment on the epigenetic profile as a reversible mechanistic link between obesity and the reproductive disorders.
methods: A PubMed search was performed using keywords related to obesity and adipose-related factors and epigenetics and associated with
keywords related to reproduction. Full-text articles and abstracts in the English language published prior to 31 December 2013 were reviewed.
results: The obesity state notably contributes to a reproductive dysfunction in both men and women, ranging from infertility to oncological
outcomes. Several epidemiological and experimental studies demonstrate that factors secreted by the adipose tissue and gut in an obesity state
can directly induce reproductive disturbances. Relevantly, these same factors are able to alter the epigenetic regulation of genes, a dynamic and re-
versible mechanism by which the organism responds to environmental pressures critical to the reproductive function.
conclusion: This review outlines the evidence showing that the associationbetween the reproductive pathologies and obesity is not inevitable
but is potentially preventable and reversible. The epigenetic marks related to obesity could constitute a therapeutic target for the reproductive dis-
orders associated with obesity.
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Introduction
Currently, obesity is a major health problem for all countries due to its
increasing prevalence and its substantial health implications related to
chronic disease and mortality. The worldwide prevalence of obesity
has nearly doubled in the last three decades. According to data from
the National Health and Nutrition Examination Survey (NHANES),
35.7% of American adults are obese, and 17% of children and adoles-
cents aged 2–19 years are obese. In Europe, over 50% of the population
is overweight, and 23% is obese. In Spain in 2006/07, 15.5% of men
and 15.2% of women were obese. Despite being a country of Mediter-
ranean diet, this prevalence in Spain rose to 22.9% in 2010 (Gutierrez-
Fisac et al., 2011).
Obesity is a multifactorial chronic disease whose etiology is an imbal-
ance between the energy ingested in food and the energy expended. This
imbalance is promoted by complex interactions between inadequate
dietary habits, diminished physical exercise and genetic background
(Marti et al., 2008). Excess energy is stored in fat cells that enlarge
and/or increase in number. This process results in an adipose tissue dys-
function and the pathological consequences of obesity that include the
development of other diseases, such as diabetes mellitus, heart
disease, neurological disease and some forms of cancer (Bray, 2004).
Obesity is instrumental in the development of type 2 diabetes mellitus
(T2D), and abdominal obesity is strongly associated with cardiovascular
disease and diabetes, even among patients with low BMI as demon-
strated by data that was generated during the International Day for the
Evaluation of Abdominal obesity (IDEA) study in Spain (Casanueva
et al., 2010). In addition to the widely known relationships of obesity
with cardiovascular disease and diabetes mellitus, obesity itself is
thought to be a relevant risk factor for reproductive disorders.
Reproductive function is controlled by the hypothalamic–pituitary–
gonadal axis, which is regulated by numerous endogenous and environ-
mental factors (Sanchez-Garrido and Tena-Sempere, 2013). Several
years ago, it was proposed that the metabolic conditions and nutritional
status influence reproductive capacity. Thus, reproductive function is
perturbed both by energy insufficiencies and energy excesses. Accord-
ingly, several epidemiological and experimental studies have provided
evidence that obesity and overweight can play relevant roles in the
early onset of reproductive features which lead to decreased rates of
conception and increases in infertility, such as puberty, menopause
and andropause, ovulatory disorders and hypogonadism (Table I). More-
over, overweight and obesity have been demonstrated to be important
risk factors for several types of cancers including those that involve the
reproduction-related tissues. However, the molecular mechanisms
that are involved in the association between obesity and reproductive
disorders remain unclear.
Here we review the current scientific evidence regarding the effects of
obesity-related factors that form the core of the collective mechanisms
that are directly and indirectly involved in the relationship between
obesity and reproductive disorders, with a special and original focus on
the effects of obesity-state microenvironment on epigenetic profile as
a reversible mechanistic link between obesity and the reproductive
disorders.
Methods
The articles selected for this review were English-language, full-text articles
and abstracts that were identified by a series of PubMed searches using
keywords either alone or in combination and published before the 31 of
December 2013. The data were extracted from the identified papers, and
secondary data sources were identified within these papers. The keywords
used included obesity, reproductive system, reproduction, reproductive
pathologies, puberty, menopause, adipose tissue, adipokines, leptin, adipo-
nectin, insulin, ghrelin, inflammation, oxidative stress, PCOS, estrogens, tes-
tosterone, ovary, testis, endometrium, breast, prostate, epigenetics and
DNA methylation.
Effects of obesity on male and
female reproductive function
The increased global prevalence of obesity has occurred concomitantly
with an apparent decline in fertility. Even though there is still insufficient
evidence to claim that human fecundity was generally declining due to
obesity, experimental studies of animal models and humans have
shown direct relationships between obesity and infertility in both
males and females.
Evidence for an association between high BMI and the periconceptual
periods of both women and men exists. Obese women seeking to
become pregnant experience longer times to conception, even if they
are young and exhibit stable menstrual cycle patterns (Jensen et al.,
1999; van der Steeg et al., 2008). In support of this observational evi-
dence, it has been demonstrated that female mice with diet-induced
obesity ovulate oocytes that exhibit developmental delays to the blasto-
cyst stage and gave rise to embryos with altered cell type proportions
(Minge et al., 2008). Moreover, the aging and function of the ovary in
women appears to be influenced by obesity as observed in the general
population (Gracia et al., 2005; Freeman et al., 2007) and, very recently,
corroborated in a cohort of female survivors of childhood cancer (van
Dorp et al., 2013). Thus, the levels of anti-Mullerian hormone
(Freeman et al., 2007; van Dorp et al., 2013) and inhibin B (Gracia
et al., 2005), which are markers of ovarian aging and ovarian function, re-
spectively, are significantly lower in healthy obese women than in non-
obese women in the menopausal transition period.
The aforementioned findings regarding the fertility of women are
similar to those for males. High BMIs (.25 kg/m2) are associated with
depletions in sperm concentrations and total sperm counts compared
with these measures in subjects with BMIs between 20 and 25 kg/m2
(Jensen et al., 2004). These alterations in spermatogenesis have also
been evidenced in animal models of genetic obesity; for example,
obese Zucker rats exhibit decreased sperm production during puberty
and increased sperm DNA fragmentation compared with their lean
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Table I Summary of the consequences of overweight
and obesity for male and female reproduction.
Reproductive landmarks Men Women
Increased time to conception + +
Early cessation of reproductive ability + ?
Hypogonadism + +
Spermatogenesis and ovulatory disorders + +
Gonadal tumorigenesis + +







upd/article/21/2/249/784796 by na user on 15 February 2021
littermates (Vendramini et al., 2014). Additionally, a recent meta-analysis
that included 21 relevant studies that were published before June 2012
(the total sample was 13 077 men) reinforced these conclusions and
revealed that overweight and obesity are associated with increased
prevalence of azoospermia and oligozoospermia (Sermondade et al.,
2013).
With increasing age, men and women reach a period of cessation of
reproductive ability, namely menopause in women and andropause or
male midlife transition in men. This age-dependent cessation in repro-
ductive function can be influenced by lifestyle factors such as obesity.
Menopause is a natural transition in the life cycle of women that is
caused by the depletion of ovarian function followed by the cessation
of menstruation. This female transition occurs most frequently at the
age of 50–51 years, but there is considerable variability across countries,
and the age of menopause can be influenced by several factors. Regarding
the effects of obesity, few studies have explored the associations
between BMI and age at menopause, and those that have are controver-
sial. Whereas some studies have observed an association between
higher BMI and later age at menopause (Henderson et al., 2008), other
studies, such as the large-cohort Fragmingham heart study, have
shown that age at natural menopause is not associated with measures
of body composition, although post-menopausal women have increased
BMI, waist circumference, visceral adipose tissue and subcutaneous
adipose tissue compared with premenopausal women (Trikudanathan
et al., 2013).
Regarding the male midlife transition, longitudinal studies of the US
population within the Massachusetts Male Aging Study (MMAS) survey
revealed that a 4-5 kg/m2 increase in BMI has a negative effect on testos-
terone that is comparable to that of 10 years of ageing (Derby et al., 2006;
Mohret al., 2006; Travison et al., 2007; Lapauw et al., 2008). Consistently,
the European Male Aging Study (EMAS), which provided one of the
largest data sets in existence for the investigation of hormonal variations
in aging men, confirmed the age-related cross-sectional trends in circu-
lating testosterone among community-dwelling men (Wu et al., 2008).
This study found that obesity is associated with progressively lower
total and free testosterone levels. Indeed, the effect of increasing BMI
on circulating testosterone is more substantial than that of age in that a
transition in BMI from non-obese to obese is equivalent to the fall in tes-
tosterone that would occur over 15 years (Wu et al., 2008). Moreover, a
prospective evaluation of the EMAS survey revealed that weight gain is
associated with suppressions of testosterone, free testosterone and
sex hormone-binding globulin (SHBG). This potential effect of obesity
on the hypothalamic–pituitary–testicular axis can be dissociated from
those of age; whereas the reductions in testosterone that are observed
with obesity are concomitant with unchanged or even reduced LH in
obese older men, age is associated with a compensatory increase in
the LH, which suggests that obesity impairs hypothalamic/pituitary func-
tion and that age affects testicular function (Wu et al., 2008).
In light of these findings, obesity appears to be a relevant determinant
of the age-related decline in reproductive function and could accelerate
the age-related infertility outcome. Therefore, even though declining fer-
tility in ageing is a prevalent feature across the animal kingdom (Jones
et al., 2014), and for men and women it will remain an inevitable fact
of life, a significant part of the age-related reproductive dysfunction
could potentially be slowed down by maintaining a healthy body weight.
In agreement with this hypothesis, interventional weight loss regimes
for obese diabetic patients result in increased testosterone (Grossmann,
2011). Moreover, a prospective evaluation of community-dwelling men
in Europe (EMAS) observed that unsupervised weight loss over 4 years of
follow-up was associated with increases in testosterone, free testoster-
one, SHBG and LH (Camacho et al., 2013).
The association between excessbody weight and polycystic ovary syn-
drome (PCOS) is particularly relevant. PCOS is the most common
female endocrine disturbance, affects 10% of the adult reproductive-
aged population and is characterized by ovarian hyperandrogenism and
chronic oligo-anovulation (Hart et al., 2004; Ehrmann, 2005). A patho-
genic role of obesity in the subsequent development of this syndrome
and the exacerbation of its phenotype has been suggested because
excess body weight frequently precedes the onset of oligomenorrhea
and hyperandrogenism and because 50% of PCOS women are over-
weight or obese (Gambineri et al., 2002; Lim et al., 2013).
Obesity and oncologic outcomes
of the reproductive system
Excess body weight has been demonstrated to be a relevant preventable
risk factor for several types of cancers (Calle et al., 2003; Renehan et al.,
2008; Boeing, 2013). Forexample, theoncologic outcomes of the gonads
can be influenced by increases in BMI. In women, obesity is a risk factor
for endometrial, ovarian, uterine cervical and breast cancer malignancies
(Reeves et al., 2007). In men, high body weight is associated with a greater
incidence of testicular tumor and more aggressive prostate cancers
(Fig. 1).
A recent meta-analysis that included 25 157 women with ovarian
cancer from 47 epidemiological studies (i.e. the majority of the available
epidemiological information worldwide) indicated that highly significant
increases in the risk of ovarian cancer accompany increases in weight
and BMI (Beral, 2012). These increases in ovarian cancer risk do not
vary with other factors that are relevant to the disease, and these
effects do not differ across the common histological subtypes of
ovarian cancer with the exception of serous tumors with borderline ma-
lignancy; for these tumors, the increase in the risk with increasing BMI is
considerably greater than that for other tumor subtypes. However, the
use of hormone therapy for menopause has a substantial effect on this
association; the relative risk of ovarian cancer is increased among
obese women who have never used menopausal hormone therapy (rela-
tive risk per every 5-unit increase in BMI of 1.10 [95% confidence interval
(CI), 1.07–1.13]) but not among those who have used hormone therapy
at some point (relative risk per every 5-unit increase in BMI of 0.95 [95%
CI, 0.92–0.99]) (Beral, 2012).
The development of cervical cancer (the third most frequent cancer
among women worldwide) is also influenced by obesity status. Obese
and overweight women appear to be at a 2-fold (odds ratio (OR) 2.1
[95% CI, 1.1–3.8]) higher risk for cervical adenocarcinoma compared
with women who are not overweight or obese (Lacey et al., 2003),
and recent observations from the Metabolic Syndrome and Cancer
Project (MeCan) cohort indicate that a 12% (hazard ratio 1.12; 95%
CI, 1.01–1.25) increase in the risk of cervical cancer risk accompanies
a 1 SD increase in BMI without differences among the histological
types of cervical cancer (Ulmer et al., 2012).
Strikingly, the strongest influences of obesity on the development of
gynecologic cancers have been observed for the risks of endometrial
and breast cancers (Renehan et al., 2008). Obesity is a major risk
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factor for endometrial cancer; the risk increases by 50–60% for every
5-unit increase in BMI, and it has been estimated that 30–34% of all endo-
metrial cancers can be attributed to overweight and obesity (Webb,
2013). This association is strongest for low-grade endometrial cancers
but is present, albeit modest, with more aggressive endometrial
cancers (Yang et al., 2012).
Obesity is a known risk factor for breast cancer (Lorincz and Sukumar,
2006). For every 5-unit increase in BMI, the risk of post-menopausal
breast cancer increases by 12% (relative risk (RR) 1.12 [95% CI, 1.08–
1.16]), and elevated BMIs are associated with a protective effect
against the development of breast cancer in premenopausal women
(RR 0.92 [95% CI, 0.88–0.97]) (Renehan et al., 2008). This association
has recently been corroborated in a study of homogeneous population
from Spain that provided evidence that the prevalence of being over-
weight/obese is significantly higher among post-menopausal breast
cancer patients (Crujeiras et al., 2012). However, although it is generally
accepted that obese women are at an increased risk for post-
menopausal breast cancer and decreased risk for premenopausal
breast cancer, a recent study provided new and consistent data that sug-
gests that there are 50 and 70% increases in the risks for premenopausal
breast cancer among overweight and obese women, respectively
(Cecchini et al., 2012). Indeed, post-menopausal obesity is more fre-
quently associated with positive estrogen receptor (ER) breast
cancers, and ages below 50 years and obesity are associated with a
higher risk for ER-negative breast cancer (Anderson and Neuhouser,
2012). Therefore, these lines of evidence suggest that reducing obesity
should be added to the cancer prevention toolbox for both pre- and
the post-menopausal breast cancer.
Regarding the effect of excess body weight on oncologic outcomes in
men, the literature has reported heterogeneous findings. Testicular
cancer is a relatively rare malignancy in the general population, but it is
the most commonly occurring cancer among young men in many coun-
tries (Chia et al., 2010). One hypothesis suggests that a high-calorie diet
and the resultant increase in body size are among the risk factors for
testicular cancer (Dieckmann et al., 2009). However, several epidemio-
logical studies have found positive associations between the risk of tes-
ticular cancer and height, and inverse or null associations of testicular
cancer with BMI and body weight (OR per every unit increase in BMI
0.99 [95% CI, 0.97–1.00]). A recent systematic reviewand meta-analysis
of body size in relation to testicular cancer corroborated these conclu-
sions (Lerro et al., 2010).
Inconsistent results regarding the association between obesity and
prostate cancer have also been published. While some studies of adult
BMI and the incidences of all prostate cancers have yielded null results,
other studies have reported that adult BMI is associated with a decrease
in prostate cancer risk among men who are diagnosed before 60 years of
age and those with family histories of prostate cancer (Rodriguez et al.,
2007). However, when the association between obesity and prostate
cancer is evaluated while accounting for the stage or grade at diagnosis,
adult BMI has been positively associated with the risk of more aggressive
tumors (RR BMI . 30 kg/m2 1.23 [95% CI, 1.00–1.55]) and inversely
associated with the risk of less-aggressive tumors (RR BMI . 30 kg/
m2 0.86 [95% CI, 0.77–1.06]) (Rodriguez et al., 2007).
The epigenetic impact of obesity
on reproductive function
The biological regulatory system through which the organism responds to
environmental pressures is mediated by epigenetic modifications to the
genome (Herceg and Vaissiere, 2011). These modifications refer to
mitotically and/or meiotically heritable changes in gene expression
that occur without altering DNA sequences (Holliday, 1987; Berger
et al., 2009). Such mechanisms play important roles in many biological
processes that occur over a person’s lifetime, including embryogenesis
and the phenotypic variations of genetically identical individuals
(Herceg and Vaissiere, 2011). The epigenetic machinery involves several
levels of regulation including DNA methylation, post-translational
Figure 1 Reproductive-related cancers associated with obesity. The data denote the relative risks of patients with BMI . 30 kg/m2 (a), relative risk per
every unit increase in BMI (b) and relative risk per every 5-units increase in BMI (c).
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histone modifications, nucleosome positioning and non-coding RNAs
(Portela and Esteller, 2010; Taby and Issa, 2010; Rodriguez-Paredes
and Esteller, 2011). Among these mechanisms, the best-known epigen-
etic marker is DNA methylation, which occurs in certain areas of the
genome with high concentrations of CpG dinucleotides (‘CpG islands’)
and leads to the silencing of both coding and non-coding genes. In add-
ition, the DNA methylation also occurs in areas of low CpG density
(,10 CpG/100 bp) named ‘CpG deserts’. Although the previous
dogma is that epigenetic modifications in CpG islands or shores
(regions up to 2 kb away from CpG islands) with highest CpG density
are critical, these ‘CpG deserts’ may be especially important for gene
regulation as it is reflected by the maintenance of small CpG clusters in
these deserts, despite the high mutation rates observed in CpG sites
(Guerrero-Bosagna et al., 2013; Skinner and Guerrero-Bosagna, 2014).
All levels of epigenetic regulation appear to have wide-ranging effects
on development and health and can be reversible. Aberrant epigenetic
regulation has been described in many human diseases including
cancer (Heyn and Esteller, 2012), obesity (Milagro et al., 2013), T2D
(Andersen et al., 2014), atherosclerosis (Zaina et al., 2014) and cardio-
vascular disease (Ordovas and Smith, 2010), neurodegenerative and
neurological diseases (Urdinguio et al., 2009; Sanchez-Mut et al., 2013)
as well as several inflammatory processes such as inflammatory bowel
disease, autoimmune diseases and rheumatoid arthritis (Glossop et al.,
2014). Therefore, epigenetic marks might explain the link between life-
style and the risk for disease and have been proposed to be sensitive bio-
markers of disease and potential therapeutic targets for disease
management (Hamilton, 2011).
Epigenetics and reproductive function
Reproductive function is highly sensitive to environmental conditions in-
cluding season, diet and exposure to chemical contaminants. In this
regards, recent reports have described epigenetic differences that
seem to be critical to reproductive function (Kurian and Terasawa,
2013). The development of the GnRH neuronal circuit is essential for re-
productive function and has been described to be influenced by epigen-
etic modifications. During development and across the onset of puberty,
increases in GnRH gene expression occur, and these increases appear to
result from DNA demethylation across a CpG island of the GnRH gene
(Kurian et al., 2010; Kurian and Terasawa, 2013). Moreover, the epigen-
etic regulation of the expression of kisspeptin, which is a major stimulant
of GnRH release, is associated with development and pubertal matur-
ation (Semaan and Kauffman, 2013). A recent study demonstrated
that the timing of puberty is under the regulatory control of an epigenetic
mechanism of transcriptional repression (Lomniczi et al., 2013). This
study provided evidence for increases in the methylation of two poly-
comb genes that are related to the transcriptional repression of several
genes (e.g. EED; embryonic ectoderm development; and CBX7; chro-
mobox homolog 7) during the onset of puberty. Pharmacological inhib-
ition of the increases in the methylation of the DNA for these two genes is
associated with delayed puberty (Lomniczi et al., 2013). Further analysis
demonstrated that EED associates with the Kiss1 promoter to reduce its
expression and consequently induces a delay of puberty and disruptions
of estrous cyclicity and fecundity (Lomniczi et al., 2013).
Epigenetic DNA modifications are also essential for spermatogenesis
and male fertility and can be affected by environmental factors. The
methylation of testes and epididymis-specific promoters is important
for spermatogenesis and sperm maturation, and aberrant changes in
the methylation of these promoters are correlated with male infertility,
carcinogenesis and development (Wu et al., 2013). Epimutations (fre-
quently hypermethylations) of several genes have been reported to be
associated with poor semen parameters or male infertility (Rajender
et al., 2010). Moreover, important genes that are expressed in the repro-
ductive tract and are relevant for spermatogenesis and male fertility, such
as the X-linked gene family of reproductive homeobox genes on the
X chromosome (RHOX) that encodes a set of homeobox genes, areepi-
genetically regulated. Hypermethylation of the X-linked RHOX cluster
may have a causal role in male infertility and may serve as a marker for
male idiopathic infertility (Richardson et al., 2014).
On the other hand, during aging, the epigenetic pattern is modified
(Fraga and Esteller, 2007; Heyn et al., 2012), and the new pattern is asso-
ciated with the onset of age-related diseases (Bell et al., 2012). There-
fore, although this issue requires further studies, the transitions to
menopause and andropause could be conditioned by age-related epi-
genetic regulation and orchestrated by environmental and lifestyle
factors such as increased body weight and obesity-related energetic
status.
Recent studies have concluded that inappropriate epigenetic repro-
gramming is also an important contributing factor to PCOS (Li and
Huang, 2008). For example, a genome-wide analysis of DNA methyla-
tion via immunoprecipitation found 40 genes in the blood cells of
PCOS women that are differentially methylated compared with those
of healthy women (Shen et al., 2013). This involvement of epigenetic
regulation in PCOS is also supported by evidence from a previous
genome-wide analysis of the visceral adipose tissue of female rhesus
monkeys that had been exposed to gestational androgen excesses (Xu
et al., 2011). More specifically, hyperandrogenism has been found to
be associated with significant alterations in the methylation status of
genes that are essential for normal reproduction and ovarian function,
such as the peroxisome proliferator-activated receptor gamma 1
(PPARG1) and nuclear corepressor 1 (NCOR1) genes, and with altera-
tions in the histone deacetylase 3 (HDAC3)-related acetylation status of
blood cells in PCOS women (Qu et al., 2012). Results consistent with
those from humans have been observed in high androgen-induced
PCOS animal models (Qu et al., 2012).
Relevantly, several types of cancer have been associated with an aber-
rant pattern of DNA methylation (Weichenhan and Plass, 2013). This
DNA methylation pattern is associated with increased risk of disease,
poor prognoses and a decreased likelihood of relapse-free survival.
For example, DNA hypermethylation of the tumor suppressor genes
(BRCA1, p16INK4a and RASSF1) and the methylation of several individ-
ual genes were recently found to be associated with clinical features of
breast cancer such as predisposition, poor prognosis and relapse-free
survival (Hill et al., 2010, 2011). Moreover, a consistent pattern of
DNA methylation across several genes has been observed in endomet-
rial and ovarian cancer (Huang et al., 2010; Catasus et al., 2013; Dehan
et al., 2013; Sanchez-Vega et al., 2013).
Frequent epigenetic aberrations, such as DNA hypo- and hyper-
methylation and altered histone acetylation and methylation, have also
been observed in prostate cancer, and these aberrations affect the ex-
pression and function of a large array of genes and lead to tumorigenesis,
tumor progression and metastasis (Dobosy et al., 2007; Li, 2007).
However, despite the extensive evidence regarding the relationship
between epigenetic aberrations and reproductive dysfunction, the
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concrete mechanisms responsible for the dysregulation of the epigenetic
machinery remain to be elucidated.
All of the aforementioned epigenetic states of different reproductive
disorders can be induced by combinations of environmental and nutri-
tional factors because epigenetic regulation may potentially be altered
by diet, age, BMI, inflammation and oxidative stress (Milagro et al.,
2013). Therefore, we hypothesize that the disturbances in reproductive
function that result from obesity may be mediated, at least in part, by the
effect of obesity-related factors on epigenetic regulation of reproductive
function, or an environmental-related epigenetic regulation can induce
an obesity state that leads to dysregulation of adipokines that then
causes reproductive disorders (Fig. 2).
Obesity-related factors, epigenetic alterations
and reproductive dysfunction
Here we review the evidence for the hypothesis that obesity induces epi-
genetic alterations, which in turn may increase susceptibility to repro-
ductive dysfunction.
Together with a dysbalance in the energy homeostasis, obesity is char-
acterized by a state of chronic low-grade inflammation that promotes
oxidative stress due to the dysfunction of adipose tissue and the altera-
tions of adipocyte-derived hormone secretion and cytokine synthesis
(Zou and Shao, 2008).
In addition to its primary role as a fuel reservoir, adipose tissue is a
highly active metabolic and endocrine organ that secretes factors that
include leptin, adiponectin, and other cytokines (Catalan et al., 2009)
and other new signals that have been identified with the proteomics ap-
proach (Roca-Rivada et al., 2011). Moreover, adipose tissue is a major
site of the metabolism of sex steroids and glucocorticoids (Kershaw
and Flier, 2004). Obesity is strongly associated with changes in the
physiological function of adipose tissue that lead to adipose tissue dys-
function, which in turn results in increased systemic levels of proinflam-
matory cytokines such as tumor necrosis factor-alpha (TNF-alpha),
interleukin 6 (IL-6), C-reactive protein and matrix metalloprotienases
(Dizdar and Alyamac, 2004). The chronic inflammation that is induced
by adipocyte dysfunction induces increases in the release and accumula-
tion of reactive oxygen species (ROS). Additionally, obesity alone
induces an excessive generation of ROS due to inefficient energy metab-
olism (Crujeiras et al., 2008). Such obesity-related inflammatory and oxi-
dative stress has been hypothesized to be a link between obesity and its
comorbidities (Vincent and Taylor, 2006).
Several enzymes involved in the epigenetic modifications utilize co-
factors or substrates that are crucial metabolites in core pathways of
intermediary metabolism such as acetyl-CoA, glucose, a-ketoglutarate
(a-KG), nicotinamide adenine dinucleotide (NAD+), flavin adenine di-
nucleotide (FAD), ATP or S-adenosylmethionine (SAM) (Gut and
Verdin, 2013). Histone acetylation primarily depends on glucose-
derived, cytosolic pools of acetyl-CoA. This chromatin modification
allows a feed-forward control mechanism for the selective expression
of genes that regulates cellular function (Gut and Verdin, 2013). There-
fore, disturbances in energy metabolism such as occur in obesity, might
Figure 2 Effects of obesity-related factors on reproductive pathologies. (a) Obesity-related factors may contribute to the process of reproductive dys-
function via the dysregulation of the epigenetic machinery (discontinuous arrows). The obesity-induced microenvironment may influence gene expression
levels and the activities of the different enzymes that are implicated in epigenetic control to induce changes in DNA methylation (hyper- or hypomethyla-
tion), post-translational histone modifications (active or repressive marks) and non-coding RNAs expression (microRNAs). These epigenetic dysregula-
tions can modify the activities of several genes that are involved in the reproductive pathways. (b) Environmental stressors, such as diet or toxicants, can lead
to epigenetic changes that promote obesity, and the obese state can contribute to dys-regulation of adipokines that then causes reproductive disorders
(continuous arrows). DNMTs, DNA methyltransferases; HMTs, histone methyltransferases; HATs, histone acetyltransferases; HDMs, histone demethy-
lases; HDAC, histone deacetylases; miR, microRNA; RHOX, reproductive homeobox genes on the X chromosome.
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also lead to stable epigenetic changes that are maintained through the
germline or they can occur in adult tissues and may affect the health of
the organism, as was recently reviewed (Gut and Verdin, 2013).
Oxidative stress induces DNA damage (e.g. base modifications, dele-
tions, strand breakages and chromosomal rearrangements) that reduces
the ability of DNA to be methylated by DNA methyltransferases
(DNMTs) and results in global hypomethylation (Wachsman, 1997;
Franco et al., 2008). Additionally, ROS can induce the hypermethylation
of certain tumor suppressor genes and thus promote carcinogenesis
(Govindarajan et al., 2002; Lim et al., 2008). Moreover, oxidative
damage has also been implicated in the regulation of histone modifica-
tions and microRNA expression (Simone et al., 2009; Mateescu et al.,
2011; Rajendran et al., 2011). Inflammation also induces epigenetic
alterations in tissues that are associated with disease manifestations, as
revealed by recent therapeutic interventions utilizing histone deacetylase
and DNMT inhibitors, the effects of certain anti-inflammatory dietary
elements on DNA methylation and chromatin remodeling, and the
actions of several inflammatory-related transcription factors such as
nuclear factor kappa B (NFkB) (Milagro et al., 2013).
This epigenetic impact of obesity on reproductive function may be
broadly divided into two areas; somatic effects and germline effects. The
obesity-related factors can induce epigenetic alterations in adult target
tissues and cells but these factors can induce an epigenetic phenotype in
germlinecells aswell, that not only impede gamete function and contribute
to infertility but also that are transmittable to the next generation.
Even though the notion that epigenetic marks are transmitted across
generations is still controversial because it is uncertain whether and to
what extent such epigenetic inheritance exists (Heard and Martienssen,
2014), over the past few years, evidence has been accumulating that epi-
genetic transgenerational inheritance occurs in mammals (Skinner et al.,
2010; Guerrero-Bosagna et al., 2013; Pembrey et al., 2014; Skinner and
Guerrero-Bosagna, 2014). In this regard, obesity status can exert a germ-
line epigenetic impact since a parental obesity effect on the reproductive
health of subsequent generations was demonstrated (Fullston et al.,
2012). Relatedly, a recent study observed that diet-induced paternal
obesity modulates sperm microRNA content and germ cell methylation
status (which are potential signals that program the health of the offspring)
and impairs the metabolic health of future generations (Fullston et al.,
2013). Similarly, maternal obesity adversely affects oocyte quality,
embryo development and the health of the offspring. The DNA methyla-
tion status of several imprinted genes and metabolism-related genes
appears to be the underlying mechanism responsible for the adverse
effects of maternal obesity on oocyte quality and the embryo develop-
ment of the offspring. These findings have recently been corroborated
in oocytes from an obesity mouse model and in oocytes and liver from
their offspring (Ge et al., 2014). The results of this study revealed that
the DNA methylation patterns of several metabolism-related genes are
not only altered in the oocytes of the obese mice but also in the
oocytes and liver of their offspring (Ge et al., 2014).
Epigenetic alterations, obesity-related factors
and reproductive dysfunction
Here we review the evidence for the hypothesis that epigenetic changes
can induce obesity, which in turn leads to reproductive dysfunction.
Specific patterns of epigenetic factors, including DNA methylation,
have also been found to be associated with obesity itself in a genome-
wide DNA methylation analysis in leucocytes and adipose tissue
(Carless et al., 2013; Xu et al., 2013; Dick et al., 2014) and in analyses
of specific genes, such as the circadian clock genes (e.g. CLOCK; clock
circadian regulator, BMAL1; aryl hydrocarbon receptor nuclear
translocator-like and PER2; period circadian 2), whose methylation
status in human leucocytes is associated with obesity (Milagro et al.,
2012). This specific epigenetic profile associated with obesity can be
induced by environmental factors on somatic cells but also a number
of studies demonstrate that ancestral environmental exposure can
promote the epigenetic transgenerational inheritance of obesity
through germline epimutations, i.e. the germline (sperm or egg) transge-
nerational transmission of epigenetic marks that influence physiological
parameters and disease, in the absence of direct environmental expo-
sures (Skinner et al., 2010). For example, a recent study demonstrated
the presence of differentially methylated regions in the sperm of the F3
generation of male rodents with ancestral exposure to the insecticide
dichlorodiphenyltrichloroethane (DDT) and a number of previously
identified obesity-associated genes correlated with the epimutations
identified (Skinner et al., 2013). This germline transmission of epimuta-
tions associated with obesity in rodents was also observed after the ex-
posure to plastics-derived endocrine disruptors (bisfenol-A,
Diethylhexyl phthalate and dibutyl phthalate) (Manikkam et al., 2013)
or jet fuel hydrocarbons(Tracey et al., 2013).
Strikingly, therapeutic strategies for counteracting excess body weight
are able to remodel DNA methylation profiles concomitant with the re-
duction of body weight. The DNA methylation and expression levels of
several genes, which are related to metabolic processes and mitochon-
drial functions (e.g. peroxisome proliferator-activated receptor gamma,
coactivator 1 alpha; PGC-1a and pyruvate dehydrogenase kinase,
isozyme 4; PDK4), are altered in the skeletal muscle of obese people
and after Roux-en-Y gastric bypass (RYGB), a type of weight-loss
surgery, and were normalized to levels observed in normal-weight,
healthy controls (Barres et al., 2013). A 6-month intervention of exercise
can induce changes in the genome-wide DNA methylation patterns of
human adipose tissue that potentially affect adipocyte metabolism
(Ronn et al., 2013). Similar results have been observed in the muscle of
patients with T2D; in these patients, exercise altered the DNA methyla-
tions of genes involved in retinol metabolism and calcium signaling path-
ways that have known functions in the muscle and T2D (Nitert et al.,
2012). The DNA methylation status of specific genes in human leuko-
cytes (Milagro et al., 2011) and adipose tissue can be altered by caloric
restriction interventions (Bouchard et al., 2010). Additionally, it has
been demonstrated that responses to weight loss treatments can be
influenced and predicted by DNA methylation status prior to beginning
treatment; i.e. differences in the DNA methylation patterns of specific
genes have been found between low and high responders to weight
loss therapy (Bouchard et al., 2010; Milagro et al., 2011) and between
patients who are prone to regain lost weight and those who are able
to maintain weight loss during a free-living period after dieting (Crujeiras
et al., 2013).
Once obesity is established, factors secreted by the dysfunctional
obese adipose tissue can directly influence reproductive function
(Budak et al., 2006; Comninos et al., 2014) and have carcinogenic prop-
erties in several tissues (Doyle et al., 2012) (Fig. 3).
Leptin, which is mainly secreted by adipose tissue and is related to
body fat, has been demonstrated to play a central role in the meta-
bolic control of the reproductive system (Carro et al., 1997;
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Casanueva and Dieguez, 1999; Pinilla et al., 1999; Tena-Sempere
et al., 1999). At the central level, endogenous leptin is required for
the activation of hypothalamic GnRH secretion and physiological
GnRH pulse generation, which are mediated by the intermediate sig-
naling factors of kisspeptin or glutamate (Comninos et al., 2014). At
high concentrations, such as those that occur in states of obesity,
leptin can directly inhibit some gonadal functions, including sex
steroid secretion; thus these inhibitory actions of leptin may explain
part of the hypogonadal states frequently observed in obese patients
(Sanchez-Garrido and Tena-Sempere, 2013).
Adiponectin is another protein that is abundantly secreted by white
adipose tissue and whose serum concentrations are inversely correlated
with body fat mass. In addition to its well-known antidiabetic, antiathero-
genic and anti-inflammatory properties (Campos et al., 2008), adiponec-
tin has been suggested to play a beneficial role in reproductive tissues.
Adiponectin has been suggested to play roles in oocyte maturation, gran-
ulosa cell proliferation and death, and as a modulator of estradiol and
progesterone secretion (Lagaly et al., 2008; Maillard et al., 2010). The de-
letion of functional adiponectin in mice results in infertility in female but
not male mice (Combs et al., 2004). Moreover, knockdown of the genes
for the adiponectin receptors Adipo R1 and Adipo R2 is associated with
increased androstenedione secretion by bovine theca cells, which
suggest that the hyperandrogenism observed in the obese and over-
weight can be explained by reductions in adiponectin in obesity
(Comim et al., 2013).
The roles of other adipose-related proteins, such as resistin and
omentin, remain to be established (Comninos et al., 2014).
Gut hormones, such as ghrelin, may also operate as modifiers of male
and female reproduction. Ghrelin is primarily secreted by the oxyntic
cells of the gastric mucosa, although it is also produced in the intestine,
pancreas, hypothalamus and pituitary (Gualillo et al., 2003). Additionally,
further evidence has demonstrated that ghrelin and its functional recep-
tor are expressed in rat and human gonads, suggesting paracrine/auto-
crine effects of this peptide in different tissues (Barreiro and
Tena-Sempere, 2004). Thus, in addition to its roles in the regulation of
feeding behavior and energy metabolism as an orexigenic signal that
increases food intake and adiposity, ghrelin has been demonstrated to
play a relevant role in the regulation of reproductive function via its inhibi-
tory effect, which has previously been reviewed elsewhere (Barreiro and
Tena-Sempere, 2004; Comninos et al., 2014). Ghrelin inhibits the prolif-
erative activity of immature Leydig cells (Barreiro et al., 2004), testoster-
one secretion in the testes (Tena-Sempere et al., 2002), and prevents
spermatogenesis (Kheradmand et al., 2012). In the female reproductive
tract, ghrelin exerts inhibitory effects on luteal function (Tropea et al.,
2007) and the biosynthesis of estradiol and progesterone in granulosa-
lutein cells (Viani et al., 2008).
Energy metabolism and reproductive function are also connected by
insulin, which is a hormone that is produced by pancreaticb-cells. In add-
ition to its function in the regulation of glucose homeostasis, this
hormone can stimulate reproductive function at the hypothalamic and
Figure 3 Links between obesity-related factors and reproductive function. The continuous arrows denote stimulatory effects, and the discontinuous
arrows indicate inhibitory effects.
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gonadal levels (Comninos et al., 2014). Hyperinsulinemia is associated
with increased LH secretion due to increased expression and secretion
of hypothalamic GnRH, particularly in females (Burcelin et al., 2003; Kim
et al., 2005). Moreover, insulin can stimulate ovarian (Nestler and
Jakubowicz, 1996; Tosi et al., 2012) and testicular (Ahn et al., 2013)
steroidogenesis.
As previously mentioned, accumulated body fat is also associated with
increased inflammation and oxidative stress (Vincent et al., 2007). The
complex interplay between cytokines and oxidative stress plays a role
in the etiologies of female and male reproductive disorders that has
been highlighted in a recent review (Agarwal et al., 2012). The oxidant
status of the cell modulates angiogenesis, which is critical for follicular
growth, corpus luteum formation, endometrial differentiation and
embryonic growth as highlighted in the aforementioned review.
Chronic inflammation has been proposed to promote delays in oocyte
development and thus the poor reproductive outcomes that are typically
observed in obese women (Robker et al., 2009). Oxidative stress also
appears to be a powerful mechanism that can lead to sperm damage, de-
formity and eventually, male infertility, as oxidative stress is toxic to
human spermatozoa (Agarwal et al., 2009; Makker et al., 2009). The in-
flammatory factors secreted by adipose tissue also appear to play an in-
hibitory role at the central level of the hypothalamic–pituitary–gonadal
axis. For example, cytokines, such as TNF-alpha and IL-6, have been
observed to dose-dependently suppress GnRH-stimulated LH release
in in vitro pituitary glands isolated from female and male rats (Russell
et al., 2001). Moreover, in rabbits with high-fat diet (HFD)-induced meta-
bolic syndrome (MetS), it has been observed that hypogonadism-
associated MetS is related to an inflammatory state that is concomitant
with a decrease in gonadotrophin levels; this finding suggests that HFD-
inducedmetabolicderangementsnegativelyaffectGnRHneuron function
via inflammatory injuries at the hypothalamic level (Morelli et al., 2014).
The above mentioned obesity-related factors are also associated with
carcinogenesis in the reproductive system (Calle and Kaaks, 2004;
Catalan et al., 2009; Khandekar et al., 2011; Howe et al., 2013). For
example, leptin induces the growth, migration and antiapoptotic func-
tions of several types of cancer cells (Li et al., 2012; Weichenhan and
Plass, 2013), and elevated circulating leptin levels in patients are corre-
lated with the risk for and progression of several cancers, such as endo-
metrial and ovarian cancers (Luhn et al., 2013), but no changes have been
observed in patients with breast cancer (Aliustaoglu et al., 2010). Insulin
has been demonstrated to be a potent mitogen that stimulates DNA syn-
thesis and appears to have a role in tumor initiation and progression
(Renehan et al., 2006). In vitro studies have demonstrated that insulin
increases the neoplastic proliferation of cell lines at both physiological
and pharmacological doses (Osborne et al., 1976; Pollak, 2008). More-
over, insulin increases the bioactivity of insulin-like growth factor I (IGF-I)
by enhancing hepatic IGF-I synthesis and by reducing the hepatic produc-
tion of IGF binding protein 1 (IGFBP-1) and 2 (IGFBP-2). IGF-I has mitotic
properties, and low levels of the expression of IGFBPs are associated
with malignant transformation (Clemmons, 2007). Therefore, although
insulin can directly induce tumor growth, many of its mitogenic and anti-
apoptotic effects operate through the IGF-I system, through increasing
the bioavailabilities of hormones, through increasing the levels of proin-
flammatory cytokines, and through oxidative stress (Arcidiacono et al.,
2012). In contrast, adiponectin has been found to exhibit anticarcino-
genic effects in vitro (Dalamaga et al., 2012), and epidemiologic studies
have shown that low levels of adiponectin are inversely associated with
the risks of developing of multiple cancers and the advanced progressions
of these diseases (Barb et al., 2007). Moreover, adiponectin inhibits
leptin-induced oncogenic signaling in vitro (Beales et al., 2014).
Therefore, the systemic alterations induced by obesity, such as hyper-
leptinemia and hyperinsulinemia, that are concomitant with low levels of
adiponectin, chronic inflammation and oxidative stress determine the
specific microenvironments in the reproductive system that are favorable
to poor reproductive outcomes and determine the onset of the
reproductive-related cancers that are typically observed in the obese.
These obesity-related factors not only can act directly to dys-regulate re-
production, but also may affect the epigenome, and these epigenetic
effects further lead to reproductive disorders (Fig. 2).
Conclusions
Several epidemiological and observational studies provide evidence for
the relationships between obesity and reproductive pathologies,
ranging from early in the onset of puberty to menopause/andropause,
and several types of tumors in the reproductive tissues. Attempts to
reduce obesity-related factors could improve reproductive function
and reduce the incidence and poor prognoses of cancers in reproductive
tissues. Although the molecular mechanisms involved in these associa-
tions require further elucidation, the molecular etiology of reproductive
disease associated with obesity could be the epigenetic changes that
could be either the result of, or cause, obesity. Obesity could contribute
to infertility and malignancies of the reproductive system by an altered
microenvironment that favors epigenetic changes that increase the sus-
ceptibility for inducing and cementing a disease state. In addition, epigen-
etic changes induced by environmental stressors can increase the
susceptibility to obesity with the consequent dys-regulation of the
obesity-related factors that obstruct the reproductive function. There-
fore, metabolic environment, chronic inflammation, oxidative stress
and deregulation of adipokine secretion that are induced by the obesity
state may play direct roles in the regulation of the hypothalamic–
pituitary–gonadal axis or indirect roles in inducing epigenetic modifica-
tions of specific genes in the reproductive pathways.
Taken together, this review highlights the need for further scientific re-
search to elucidate the role of epigenetic regulation as a potential mech-
anistic link between obesity and disturbances in reproductive function.
Because epigenetic modifications are dynamic and reversible and
change in response to dietary patterns, physical activity and weight
loss, the epigenetic markers related to obesity may constitute therapeut-
ic targets for the prevention of obesity-related disorders including repro-
ductive pathologies. Future efforts will therefore be needed to carry out
genome-wide analysis that provides information on reproductive
dysfunction-specific epigenetic marks and longitudinal studies will be
required to evaluate the effect of dietary- or surgery-induced weight
loss on reprogramming these disease-specific epigenetic modifications.
Understanding the influence of the obesity-related microenvironment
on epigenetic regulation of the reproductive function machinery will
provide new tools to improve the management as well as the prevention
of reproductive disorders.
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